The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. CytomX Therapeutics Inc shares valued at $28,540 were sold by Ogden Christopher on Jun 16 ’25. At $2.69 per share, Ogden Christopher sold 10,614 shares. The insider’s holdings dropped to 226,271 shares worth approximately $0.46 million following the completion of this transaction.
Also, Ogden Christopher sold 1,641 shares, netting a total of over 4,841 in proceeds. Following the sale of shares at $2.95 each, the insider now holds 199,385 shares.
Before that, BELVIN MARCIA had sold 13,884 shares from its account. In a trade valued at $37,334, the SVP, Chief Scientific Officer traded CytomX Therapeutics Inc shares for $2.69 each. Upon closing the transaction, the insider’s holdings decreased to 13,884 shares, worth approximately $0.56 million.
As published in their initiating research note from Oppenheimer on July 31, 2025, CytomX Therapeutics Inc [CTMX] has been an Outperform and the price target has been revised to $7. Analysts at H.C. Wainwright upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in mid May. Earlier on May 28, 2024, Piper Sandler upgraded its rating. Their new recommendation was “an Overweight” for CTMX stock which previously was a “a Neutral”.
Analyzing CTMX Stock Performance
On last trading session, CytomX Therapeutics Inc [NASDAQ: CTMX] plunged -0.97% to $2.05. The stock’s lowest price that day was $2.05, but it reached a high of $2.1746 in the same session. During the last five days, there has been a surge of approximately 0.99%. Over the course of the year, CytomX Therapeutics Inc shares have jumped approximately 72.27%. Shares of the company reached a 52-week high of $3.10 on 06/13/25 and a 52-week low of $0.40 on 04/07/25.
Support And Resistance Levels for CytomX Therapeutics Inc (CTMX)
According to the 24-hour chart, there is a support level at 2.01, which, if violated, would cause prices to drop to 1.97. In the upper region, resistance lies at 2.13. The next price resistance is at 2.22. RSI (Relative Strength Index) is 46.96 on the 14-day chart, showing neutral technical sentiment.
Is CytomX Therapeutics Inc subject to short interest?
Stocks of CytomX Therapeutics Inc saw a sharp rise in short interest on 2025-08-15 jumping by 1.27 million shares to 25.14 million. Data from Yahoo Finance shows that the short interest on 2025-07-15 was 23.87 million shares. A jump of 5.05% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 9.14 of the overall float, the days-to-cover ratio (short ratio) jumped to 9.14.
Which companies own the most shares of CytomX Therapeutics Inc (CTMX)?
In terms of CytomX Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 7 in the next 12 months, up nearly 238.16% from the previous closing price of $2.07. Analysts anticipate CytomX Therapeutics Inc stock to reach 7 by 2025, with the lowest price target being 7. In spite of this, 4 analysts ranked CytomX Therapeutics Inc stock as Buy at the end of 2025. On May 09, 2024, Wedbush assigned a price target of “an Outperform” to the stock and upgraded coverage with a $8.
